2. Daudon M., Frochot V., Bazin D., Jungers P. Drug- Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment. Drugs. 2018;78(2):163–201. Doi: 10.1007/s40265-017- 0853-7.

3. Daudon M., Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004;64(3):245–75. Doi: 10.2165/00003495- 200464030-00003.

4. Ulinski T., Sabot J.F., Bourlon I., Cochat P. Bilateral urinary calculi after treatment with a silicate-containing milk thickener. Eur J Pediatr. 2004;163(4–5):239–40. Doi: 10.1007/s00431-004-1400-6.

5. Montagnac R., Briat C., Schillinger F., et al. Fluoroquinolone induced acute renal failure. General review about a case report with crystalluria due to ciprofloxacin. Nephrol Ther. 2005;1(1):44–51. French. Doi: 10.1016/j.nephro.2005.02.005.

6. Sedlacek M., Suriawinata A.A., Schoolwerth A., Remillard B.D. Ciprofloxacin crystal nephropathy – a ‘new’ cause of acute renal failure. Nephrol Dial Transplant. 2006;21(8):2339–40. Doi: 10.1093/ ndt/gfl160.

7. Khan M., Ortega L.M., Bagwan N., Nayer A. Crystal- induced acute kidney injury due to ciprofloxacin. J Nephropathol. 2015;4(1):29–31. Doi: 10.12860/ jnp.2015.06.

8. Dobrek Ł. Kidney stone disease with special regard to drug-induced kidney stones – a contemporary synopsis. Wiad Lek. 2020;73(9 cz. 2):2031–39. Doi: 10.36740/WLek202009226.

9. Wiseman L.R., Balfour J.A. Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging. 1994;4(2):145–73. Doi: 10.2165/00002512-199404020-00007.

10. Thorsteinsson S.B., Bergan T., Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy. 1988;34(3):256–60. Doi: 10.1159/000238577.

11. Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem. 1986;24:767–68.

12. Chutipongtanate S., Thongboonkerd V. Ceftriaxone crystallization and its potential role in kidney stone formation. Biochem Biophys Res Commun. 2011;406(3):396–402. Doi: 10.1016/j. bbrc.2011.02.053.

13. de Moor R.A., Egberts A.C., Schröder C.H. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr. 1999;158(12):975–77. Doi: 10.1007/ s004310051261.

14. Zhang Y., Ning B., Zhu H., et al. Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review. Int Urol Nephrol. 2016;48(7):1061–69. Doi: 10.1007/ s11255-016-1273-4.

15. Dichiara A.J., Atkinson M., Goodman Z., Sherman K.E. Ciprofloxacin-induced acute cholestatic liver injury and associated renal failure. Case report and review. Minerva Gastroenterol Dietol. 2008;54(3):307–15.

16. Garnier A.S., Dellamaggiore J., Brilland B., et al. High Incidence of Amoxicillin-Induced Crystal Nephropathy in Patients Receiving High Dose of Intravenous Amoxicillin. J Clin Med. 2020;9(7):2022. Doi: 10.3390/jcm9072022.

17. Fogazzi G.B., Cantù M., Saglimbeni L., Daudon M. Amoxycillin, a rare but possible cause of crystalluria. Nephrol Dial Transplant. 2003;18(1):212–14. Doi: 10.1093/ndt/18.1.212.

18. Assimos D.G., Langenstroer P., Leinbach R.F, et al. Guaifenesin- and ephedrine-induced stones. J Endourol. 1999;13(9):665–67. Doi: 10.1089/ end.1999.13.665.

19. Small E., Sandefur B.J. Acute renal failure after ingestion of guaifenesin and dextromethorphan. J Emerg Med. 2014;47(1):26–9. Doi: 10.1016/j. jemermed.2014.01.022.

20. Song G.Y., Lockhart M.E., Smith J.K., et al. Pseudoephedrine and guaifenesin urolithiasis: widening the differential diagnosis of radiolucent calculi on abdominal radiograph. Abdom. Imaging. 2005;30(5):644–46. Doi: 10.1007/s00261-004- 0294-0.

21. Gabardi S., Carter D., Martin S., Roberts K. Recommendations for the proper use of nonprescription cough suppressants and expectorants in solid-organ transplant recipients. Prog Transplant. 2011;21(1):6–13;quiz 14. Doi: 10.7182/ prtr.21.1.t837123h2350721j.

22. Powell T., Hsu F.F., Turk J., Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998;32(1):153–9. Doi: 10.1053/ajkd.1998.v32.pm9669437.

23. Blau J.J. Ephedrine nephrolithiasis associated with chronic ephedrine abuse. J Urol. 1998;160(3 Pt. 1):825. Doi: 10.1097/00005392-199809010- 00052.

24. Bennett S., Hoffman N., Monga M. Ephedrine- and guaifenesin-induced nephrolithiasis. J Altern Complement Med. 2004;10(6):967–69. Doi: 10.1089/acm.2004.10.967.

25. Hoffman N., McGee S.M., Hulbert J.C. Resolution of ephedrine stones with dissolution therapy. J Urol. 2003;61(5):1035. Doi: 10.1016/s0090- 4295(02)02593-1.

26. Perazella M.A. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–65. Doi: 10.1016/s0002- 9343(99)00041-8.

27. Yarlagadda S.G., Perazella M.A. Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf. 2008;7(2):147–58. Doi: 10.1517/14740338.7.2.147.

28. Hagos Y., Wolff N.A. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel). 2010;2(8):2055–82. Doi: 10.3390/toxins2082055.

29. Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703. Doi: 10.1634/ theoncologist.11-6-694.

30. Jackson R.D., LaCroix A.Z., Gass M., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669–83. Doi: 10.1056/ NEJMoa055218.

31. Lappe J., Watson P., Travers-Gustafson D., et al. Effect of vitamin D an calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA. 2017;317(12):1234–43. Doi: 10.1001/ jama.2017.2115.

32. Hu H., Zhang J., Lu Y., et al. Association between Circulating Vitamin D Level and Urolithiasis: A Systematic Review and Meta-Analysis. Nutrients. 2017;9(3):301. Doi: 10.3390/nu9030301.

33. Pak C.Y., Sakhaee K., Hwang T.I., et al. Nephrolithiasis from calcium supplementation. J Urol. 1987;137(6):1212–13. Doi: 10.1016/s0022- 5347(17)44455-7.

34. Molin A., BauDoin R., Kaufmann M., et al. CYP24A1 Mutations in a Cohort of Hypercalcemic Patients: Evidence for a Recessive Trait. J. Clin. Endocrinol. Metab. 2015;100(10):E1343–52. Doi: 10.1210/ jc.2014-4387.

35. Alelign T., Petros B. Kidney Stone Disease: An Update on Current Concepts. Adv Urol. 2018;2018:3068365. Doi: 10.1155/2018/3068365.

36. Levine B.S., Rodman J.S., Wienerman S., et al. Effect of calcium citrate supplementation on urinary calcium oxalate saturation in female stone formers: implications for prevention of osteoporosis. Am J Clin Nutr. 1994;60(4):592–96. Doi: 10.1093/ ajcn/60.4.592.

37. Harris S.S., Dawson-Hughes B. Effects of Hydration and Calcium Supplementation on Urine Calcium Concentration in Healthy Postmenopausal Women. J Am Coll Nutr. 2015;34(4):340–46. Doi: 10.1080/07315724.2014.959207.

38. Ferraro P.M., Curhan G.C., Gambaro G., et al. Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones. Am J Kidney Dis. 2016;67(3):400–7. Doi: 10.1053/j.ajkd.2015.09.005.

39. Thomas L.D., Elinder C.G., Tiselius H.G., et al. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA. Intern Med. 2013;173(5):386–88. Doi: 10.1001/ jamainternmed.2013.2296.

40. Hoffer L.J., Levine M., Assouline S., et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008;19(11):1969–74. Doi: 10.1093/ annonc/mdn377.

41. Robitaille L., Mamer O.A., Miller W.H. Jr, et al. Oxalic acid excretion after intravenous ascorbic acid administration. Metab. 2009;58(2):263–69. Doi: 10.1016/j.metabol.2008.09.023.

42. rlsnet.ru (электронный ресурс). РЛС. Реестр лекарственных средств России. Ацетазоламид (доступ от 15.01.2022).

43. Daudon M., Jungers P. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol. 2004;98(2):31–6. Doi: 10.1159/000080261.

44. Ahlstrand C., Tiselius H.G. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol. 1987;21(3):225–28. Doi: 10.3109/00365598709180326.

45. Higashihara E., Nutahara K., Takeuchi T., et al. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate. J Urol. 1991;145(5):942–48. Doi: 10.1016/s0022- 5347(17)38496-3.

46. Sakhaee K., Maalouf N.M., Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012;97(6):1847–60. Doi: 10.1210/ jc.2011-3492.

47. Scozzafava A., Supuran C.T. Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–59. Doi: 10.1007/978-94- 007-7359-2_17.

48. Maalouf N.M., Langston J.P., Van Ness P.C., et al. Nephrolithiasis in topiramate users. Urol Res. 2011;39(4):303–7. Doi: 10.1007/s00240-010- 0347-5.

49. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23(8):1765–73. Doi: 10.1185/030079907X210499.

50. Go T. Zonisamide Induces Crystalluria without Urinary pH Changes in Children and Young Adults. ISRN Neurol. 2013;2013:841902. Doi: 10.1155/2013/841902.

51. Sheth R.D. Metabolic concerns associated with antiepileptic medications. Neurol. 2004;63(10 Suppl. 4):S24–9. Doi: 10.1212/wnl.63.10_suppl_4.s24.

52. Sato S., Nishinaka K., Takahashi S., et al.

53. Schell-Feith E.A., Kist-van Holthe J.E., van der Heijden A.J. Nephrocalcinosis in preterm neonates. Pediatr Nephrol. 2010;25(2):221–230. Doi: 10.1007/ s00467-008-0908-9.

54. Gimpel C., Krause A., Franck P., et al. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. Pediatr Int. 2010;52(1):51–6. Doi: 10.1111/j.1442- 200X.2009.02886.x

55. Mohamed G.B., Ibrahiem M.A., Abdel Hameed W.M. Nephrocalcinosis in pre-term neonates: a study of incidence and risk factors. Saudi J Kidney Dis Transpl. 2014;25(2):326–32. Doi: 10.4103/1319- 2442.128524.

56. Kim Y.G., Kim B., Kim M.K., et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant. 2001;16(12):2303–309. Doi: 10.1093/ ndt/16.12.2303.

57. Pacifici G.M. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. Paediatr Drugs. 2012;14(4):233–46. Doi: 10.2165/11596620-000000000-00000.

58. Blickman J.G., Herrin J.T., Cleveland R.H., Jaramillo D. Coexisting nephrolithiasis and cholelithiasis in premature infants. Pediatr Radiol. 1991;21(5):363– 64. Doi: 10.1007/BF02011489.

59. Pattaragarn A., Fox J., Alon U.S. Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int. 2004;65(5):1684–89. Doi: 10.1111/j.1523- 1755.2004.00564.x.

60. Chu D.I., Tasian G.E., Copelovitch L. Pediatric Kidney Stones – Avoidance and Treatment. Curr Treat Options Pediatr. 2016;2(2):104–11. Doi: 10.1007/s40746- 016-0046-8.

61. Hufnagle K.G., Khan S.N., Penn D., et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatr. 1982; 70(3):360–63.

62. Alon U.S., Scagliotti D., Garola R.E. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr. 1994;125(1):149–51. Doi: 10.1016/s0022- 3476(94)70143-1.

63. Ali S.K. Renal calculi complicating short-term furosemide therapy after congenital heart surgery. Congenit Heart Dis. 2006;1(5):251–53. Doi: 10.1111/j.1747-0803.2006.00044.x.

64. Torres R.J., Prior C., Puig J.G. Efficacy and safety of allopurinol in patients with hypoxanthine- guanine phosphoribosyltransferase deficiency. Metab. 2007;56(9):1179–86. Doi: 10.1016/j. metabol.2007.04.013.